On August 19, 2025, Silexion Therapeutics Corp increased its authorized share capital from $20,000 to $121,500, allowing for up to 9,000,000 ordinary shares after shareholder approval. 1,459,924 shares, or 16.8%, attended the meeting, with 59.8% voting in favor.